Cuellar-Herrera, ManolaLuisa Velasco, AnaVelasco, FranciscoChavez, LauraOrozco-Suarez, SandraArmagan, GulizTurunc, EzgiBojnik, EnginYalcin, AyferBenyhe, SandorBorsodi, AnnaAlonso-Vanegas, MarioRocha, Luisa2019-10-272019-10-2720121050-9631https://doi.org/10.1002/hipo.20891https://hdl.handle.net/11454/47299Mu opioid receptors (MOR) are known to be involved in seizure activity. The main goal of the present study was to characterize the MOR mRNA expression, binding, as well as G protein activation mediated by these receptors in epileptic hippocampus of patients with pharmacoresistant mesial temporal lobe epilepsy (TLE). In contrast with autopsy samples, hippocampus obtained from patients with mesial TLE demonstrated enhanced MOR mRNA expression (116%). Saturation binding experiments revealed significantly higher (60%) Bmax values for the mesial TLE group, whereas the Kd values were not statistically different. Although mesial TLE group demonstrated high levels of basal binding for the G proteins (136%), DAMGO-stimulated [35S]GTP?S binding did not demonstrate significant alterations. In conclusion, our present data provide strong evidence that the epileptic hippocampus of patients with pharmacoresistant mesial TLE presents significant alterations in MOR. Such changes may represent adaptive mechanisms to compensate for other as yet unknown alterations. (C) 2010 Wiley Periodicals, Inc.en10.1002/hipo.20891info:eu-repo/semantics/closedAccessmu opiod receptormRNAG-proteinbindinghippocampusmesial temporal lobe epilepsyArticle222122127WOS:00029925040000221049484N/AQ1